Meenhard Herlyn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7582703/publications.pdf

Version: 2024-02-01

164 papers	25,161 citations	9756 73 h-index	7333 152 g-index
174 all docs	174 docs citations	174 times ranked	31382 citing authors

#	Article	IF	Citations
1	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature, 2018, 560, 382-386.	13.7	1,836
2	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3041-3046.	3.3	1,206
3	A Tumorigenic Subpopulation with Stem Cell Properties in Melanomas. Cancer Research, 2005, 65, 9328-9337.	0.4	1,200
4	Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 2010, 18, 683-695.	7.7	1,139
5	A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth. Cell, 2010, 141, 583-594.	13.5	1,052
6	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature, 2017, 546, 431-435.	13.7	938
7	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell, 2018, 175, 984-997.e24.	13.5	892
8	BRAF and RAS mutations in human lung cancer and melanoma. Cancer Research, 2002, 62, 6997-7000.	0.4	848
9	Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells. Cancer Cell, 2013, 23, 811-825.	7.7	553
10	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell & Melanoma Research, 2006, 19, 290-302.	4.0	483
11	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine, 2018, 24, 1545-1549.	15.2	473
12	Regulation of Notch1 and Dll4 by Vascular Endothelial Growth Factor in Arterial Endothelial Cells: Implications for Modulating Arteriogenesis and Angiogenesis. Molecular and Cellular Biology, 2003, 23, 14-25.	1.1	456
13	Enhancing CD8+ T Cell Fatty Acid Catabolism withinÂa Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell, 2017, 32, 377-391.e9.	7.7	419
14	Melanoma. Nature Reviews Disease Primers, 2015, 1, 15003.	18.1	417
15	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Molecular Cancer Therapeutics, 2006, 5, 1136-1144.	1.9	410
16	<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery, 2018, 8, 196-215.	7.7	392
17	Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Research, 2003, 63, 756-9.	0.4	340
18	Isolation of a Novel Population of Multipotent Adult Stem Cells from Human Hair Follicles. American Journal of Pathology, 2006, 168, 1879-1888.	1.9	336

#	ARTICLE	IF	CITATIONS
19	E-Cadherin Expression in Melanoma Cells Restores Keratinocyte-Mediated Growth Control and Down-Regulates Expression of Invasion-Related Adhesion Receptors. American Journal of Pathology, 2000, 156, 1515-1525.	1.9	320
20	Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell & Melanoma Research, 2005, 18, 150-159.	4.0	304
21	Activation of Notch1 signaling is required for Â-catenin-mediated human primary melanoma progression. Journal of Clinical Investigation, 2005, 115, 3166-3176.	3.9	293
22	Rewired ERK-JNK Signaling Pathways in Melanoma. Cancer Cell, 2007, 11, 447-460.	7.7	260
23	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. Cancer Discovery, 2019, 9, 64-81.	7.7	260
24	LIFE ISN'T FLAT: TAKING CANCER BIOLOGY TO THE NEXT DIMENSION. In Vitro Cellular and Developmental Biology - Animal, 2006, 42, 242.	0.7	258
25	Notch1 Signaling Promotes Primary Melanoma Progression by Activating Mitogen-Activated Protein Kinase/Phosphatidylinositol 3-Kinase-Akt Pathways and Up-regulating N-Cadherin Expression. Cancer Research, 2006, 66, 4182-4190.	0.4	251
26	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nature Communications, 2019, 10, 4186.	5.8	236
27	Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. Cell Reports, 2013, 3, 1252-1265.	2.9	228
28	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Frontiers in Bioscience - Landmark, 2005, 10, 2986.	3.0	227
29	An Organometallic Protein Kinase Inhibitor Pharmacologically Activates p53 and Induces Apoptosis in Human Melanoma Cells. Cancer Research, 2007, 67, 209-217.	0.4	224
30	Epidermal Growth Factor Receptor Mediates Increased Cell Proliferation, Migration, and Aggregation in Esophageal Keratinocytes in Vitro and in Vivo. Journal of Biological Chemistry, 2003, 278, 1824-1830.	1.6	220
31	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. Journal of Clinical Investigation, 2016, 126, 1834-1856.	3.9	219
32	Melanomaâ€“stroma interactions: structural and functional aspects. Lancet Oncology, The, 2002, 3, 35-43.	5.1	214
33	Human Melanoma Progression in Skin Reconstructs. American Journal of Pathology, 2000, 156, 193-200.	1.9	203
34	Adenoviral Gene Transfer of Î²3 Integrin Subunit Induces Conversion from Radial to Vertical Growth Phase in Primary Human Melanoma. American Journal of Pathology, 1998, 153, 1435-1442.	1.9	199
35	Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2. Cancer Discovery, 2013, 3, 1378-1393.	7.7	197
36	Normal Human Melanocyte Homeostasis as a Paradigm for Understanding Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 2005, 10, 153-163.	0.8	177

#	ARTICLE	IF	CITATIONS
37	Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene, 2001, 20, 8125-8135.	2.6	173
38	Melanoma and the tumor microenvironment. Current Oncology Reports, 2008, 10, 439-446.	1.8	173
39	Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somatic Cell and Molecular Genetics, 1985, 11, 297-302.	0.7	169
40	Melanoma development and progression: a conspiracy between tumor and host. Differentiation, 2002, 70, 522-536.	1.0	168
41	Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma. Cell Reports, 2013, 4, 1090-1099.	2.9	162
42	Human dermal stem cells differentiate into functional epidermal melanocytes. Journal of Cell Science, 2010, 123, 853-860.	1.2	153
43	Melanoma Stem Cells: The Dark Seed of Melanoma. Journal of Clinical Oncology, 2008, 26, 2890-2894.	0.8	149
44	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature, 2017, 550, 133-136.	13.7	146
45	Up-Regulated Expression of Zonula Occludens Protein-1 in Human Melanoma Associates with N-Cadherin and Contributes to Invasion and Adhesion. American Journal of Pathology, 2005, 166, 1541-1554.	1.9	143
46	PLX4032, a potent inhibitor of the Bâ€Raf V600E oncogene, selectively inhibits V600Eâ€positive melanomas. Pigment Cell and Melanoma Research, 2010, 23, 820-827.	1.5	142
47	The Role of Altered Cellâ€“Cell Communication in Melanoma Progression. Journal of Molecular Histology, 2003, 35, 309-318.	1.0	135
48	Pre-clinical modeling of cutaneous melanoma. Nature Communications, 2020, 11, 2858.	5.8	133
49	Fibroblastâ€dependent differentiation of human microvascular endothelial cells into capillaryâ€like, threeâ€dimensional networks. FASEB Journal, 2002, 16, 1316-1318.	0.2	130
50	The Essential Role of Fibroblasts in Esophageal Squamous Cell Carcinomaâ€“Induced Angiogenesis. Gastroenterology, 2008, 134, 1981-1993.	0.6	118
51	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	9.4	118
52	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports, 2017, 21, 1953-1967.	2.9	117
53	Progression-related expression of Î²3 integrin in melanomas and nevi. Human Pathology, 1999, 30, 562-567.	1.1	116
54	Defining the Conditions for the Generation of Melanocytes from Human Embryonic Stem Cells. Stem Cells, 2006, 24, 1668-1677.	1.4	113

#	ARTICLE	IF	CITATIONS
55	Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene, 1999, 18, 6469-6476.	2.6	111
56	Fibroblasts Contribute to Melanoma Tumor Growth and Drug Resistance. Molecular Pharmaceutics, 2011, 8, 2039-2049.	2.3	109
57	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications, 2017, 8, 607.	5.8	109
58	Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment. Cancer Research, 2013, 73, 4383-4394.	0.4	108
59	Personalized Preclinical Trials in BRAF Inhibitorâ€"Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. Clinical Cancer Research, 2016, 22, 1592-1602.	3.2	108
60	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	5.8	107
61	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. Clinical Cancer Research, 2015, 21, 1652-1664.	3.2	106
62	<i>In vitro</i>three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opinion on Drug Discovery, 2008, 3, 1-10.	2.5	105
63	Active Notch1 Confers a Transformed Phenotype to Primary Human Melanocytes. Cancer Research, 2009, 69, 5312-5320.	0.4	103
64	Dynamics of intercellular communication during melanoma development. Trends in Molecular Medicine, 2000, 6, 163-169.	2.6	100
65	A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors. Cancer Research, 2011, 71, 6836-6847.	0.4	99
66	Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB Journal, 2006, 20, 1009-1011.	0.2	98
67	The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. Clinical Cancer Research, 2013, 19, 1784-1794.	3.2	98
68	Polyunsaturated Fatty Acids from Astrocytes Activate PPARÎ³ Signaling in Cancer Cells to Promote Brain Metastasis. Cancer Discovery, 2019, 9, 1720-1735.	7.7	97
69	Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Research, 1997, 7, S43.	0.6	96
70	CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. Journal of Cell Biology, 2006, 175, 563-569.	2.3	94
71	Identification of a Novel Subgroup of Melanomas with KIT/Cyclin-Dependent Kinase-4 Overexpression. Cancer Research, 2008, 68, 5743-5752.	0.4	90
72	Melanoma models for the next generation of therapies. Cancer Cell, 2021, 39, 610-631.	7.7	90

#	ARTICLE	IF	CITATIONS
73	Developmental pathways activated in melanocytes and melanoma. Archives of Biochemistry and Biophysics, 2014, 563, 13-21.	1.4	84
74	Induction of Melanoma Phenotypes in Human Skin by Growth Factors and Ultraviolet B. Cancer Research, 2004, 64, 807-811.	0.4	82
75	Coâ€targeting <scp>BET</scp> and <scp>MEK</scp> as salvage therapy for <scp>MAPK</scp> and checkpoint inhibitorâ€resistant melanoma. EMBO Molecular Medicine, 2018, 10, .	3.3	79
76	Microenvironmental influences in melanoma progression. Journal of Cellular Biochemistry, 2007, 101, 862-872.	1.2	77
77	<scp>W</scp>nt5<scp>A</scp> promotes an adaptive, senescentâ€like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell and Melanoma Research, 2015, 28, 184-195.	1.5	77
78	Functional Erythropoietin Autocrine Loop in Melanoma. American Journal of Pathology, 2005, 166, 823-830.	1.9	75
79	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. Cancer Discovery, 2020, 10, 1282-1295.	7.7	75
80	Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene, 2001, 20, 4676-4684.	2.6	72
81	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports, 2017, 21, 1936-1952.	2.9	72
82	Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence. Molecular Therapy, 2012, 20, 1056-1062.	3.7	69
83	The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression. Journal of Visualized Experiments, 2011, , .	0.2	68
84	Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine, 2021, 27, 985-992.	15.2	67
85	Stromal changes in the aged lung induce an emergence from melanoma dormancy. Nature, 2022, 606, 396-405.	13.7	67
86	The many faces of Notch signaling in skin-derived cells. Pigment Cell & Melanoma Research, 2007, 20, 458-465.	4.0	64
87	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget, 2017, 8, 25395-25417.	0.8	64
88	Heterogeneity in Melanoma. Cancer Treatment and Research, 2016, 167, 1-15.	0.2	59
89	Dermisâ€derived stem cells: a source of epidermal melanocytes and melanoma?. Pigment Cell and Melanoma Research, 2011, 24, 422-429.	1.5	58
90	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications, 2021, 12, 5086.	5.8	58

#	ARTICLE	IF	CITATIONS
91	The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling. PLoS ONE, 2013, 8, e59588.	1.1	58
92	Direct Reprogramming of Melanocytes to Neural Crest Stem-Like Cells by One Defined Factor. Stem Cells, 2011, 29, 1752-1762.	1.4	55
93	Truncation of Activated Leukocyte Cell Adhesion Molecule: A Gateway to Melanoma Metastasis. Journal of Investigative Dermatology, 2004, 122, 1293-1301.	0.3	53
94	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Seminars in Cancer Biology, 2005, 15, 451-459.	4.3	53
95	The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research, 2021, 27, 2678-2697.	3.2	53
96	Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle, 2011, 10, 2008-2016.	1.3	51
97	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.4	51
98	Growth and Phenotoypic Characteristics of Human Nevus Cells in Culture. Journal of Investigative Dermatology, 1988, 90, 134-141.	0.3	50
99	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. Journal of Cell Communication and Signaling, 2016, 10, 191-196.	1.8	49
100	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Research, 2016, 76, 5538-5549.	0.4	46
101	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. Molecular Cell, 2020, 77, 633-644.e5.	4.5	45
102	Interactions of Melanocytes and Melanoma Cells With the Microenvironment. Pigment Cell & Melanoma Research, 1994, 7, 81-88.	4.0	43
103	In Vitro Growth Patterns of Normal Human Melanocytes and Melanocytes from Different Stages of Melanoma Progression. Journal of Immunotherapy, 1992, 12, 199-202.	1.2	41
104	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. Experimental Dermatology, 2015, 24, 155-157.	1.4	41
105	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	7.7	40
106	Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. Cancer Research, 2002, 62, 226-32.	0.4	39
107	Old disease, new culprit: Tumor stem cells in cancer. Journal of Cellular Physiology, 2007, 213, 603-609.	2.0	37
108	GSK3Î² Inhibition Blocks Melanoma Cell/Host Interactions by Downregulating N-Cadherin Expression and Decreasing FAK Phosphorylation. Journal of Investigative Dermatology, 2012, 132, 2818-2827.	0.3	37

#	Article	IF	Citations
109	VEGFâ€A and Î± V Î² 3 integrin synergistically rescue angiogenesis via Nâ€Ras and PI3â€K signaling in human microvascular endothelial cells. FASEB Journal, 2003, 17, 1-21.	0.2	36
110	Oncogenic RAS Regulates Long Noncoding RNA <i>Orilnc1</i> in Human Cancer. Cancer Research, 2017, 77, 3745-3757.	0.4	34
111	Matricellular Proteins Produced by Melanocytes and Melanomas: In Search for Functions. Cancer Microenvironment, 2008, 1, 93-102.	3.1	33
112	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene, 2021, 40, 5590-5599.	2.6	33
113	Comparative Secretome Analysis of Epithelial and Mesenchymal Subpopulations of Head and Neck Squamous Cell Carcinoma Identifies S100A4 as a Potential Therapeutic Target. Molecular and Cellular Proteomics, 2013, 12, 3778-3792.	2.5	32
114	Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding Î²-catenin signaling. Experimental Cell Research, 2004, 297, 142-151.	1.2	31
115	Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nature Communications, 2022, 13, 1381.	5.8	31
116	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. Cancer Discovery, 2021, 11, 1716-1735.	7.7	30
117	The role of Oraiâ€“STIM calcium channels in melanocytes and melanoma. Journal of Physiology, 2016, 594, 2825-2835.	1.3	29
118	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research, 2018, 24, 4771-4784.	3.2	29
119	MSX1-Induced Neural Crest-Like Reprogramming Promotes MelanomaÂProgression. Journal of Investigative Dermatology, 2018, 138, 141-149.	0.3	29
120	TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. Nature Cell Biology, 2021, 23, 978-991.	4.6	29
121	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. Cancer Research, 2017, 77, 5873-5885.	0.4	26
122	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. Clinical Cancer Research, 2019, 25, 2783-2794.	3.2	25
123	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clinical Cancer Research, 2020, 26, 6039-6050.	3.2	24
124	EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas. Molecular Cancer Therapeutics, 2013, 12, 2176-2186.	1.9	23
125	HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors. Nature Communications, 2022, 13, .	5.8	23
126	Nivolumab in combination with ipilimumab for the treatment of melanoma. Expert Review of Anticancer Therapy, 2015, 15, 1135-1141.	1.1	22

#	ARTICLE	IF	CITATIONS
127	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8001-8012.	3.3	21
128	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nature Communications, 2021, 12, 6023.	5.8	21
129	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. Expert Review of Anticancer Therapy, 2005, 5, 1069-1078.	1.1	20
130	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. Journal of Investigative Dermatology, 2021, 141, 1564-1572.e4.	0.3	20
131	Persister state-directed transitioning and vulnerability in melanoma. Nature Communications, 2022, 13, .	5.8	20
132	Isolation and Cultivation of Dermal Stem Cells that Differentiate into Functional Epidermal Melanocytes. Methods in Molecular Biology, 2012, 806, 15-29.	0.4	18
133	UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crestâ€“Like Cells via Suppression of Notch. Journal of Investigative Dermatology, 2015, 135, 1521-1532.	0.3	18
134	Nongenetic Mechanisms of Drug Resistance in Melanoma. Annual Review of Cancer Biology, 2020, 4, 315-330.	2.3	18
135	Molecular targets in melanoma: Strategies and challenges for diagnosis and therapy. International Journal of Cancer, 2006, 118, 523-526.	2.3	16
136	Integrating tumorâ€initiating cells into the paradigm for melanoma targeted therapy. International Journal of Cancer, 2009, 124, 1245-1250.	2.3	15
137	Isolation, Characterization, and Differentiation of Human Multipotent Dermal Stem Cells. Methods in Molecular Biology, 2013, 989, 235-246.	0.4	14
138	Costimulation of Î³Î´TCR and TLR7/8 promotes VÎ´2 T-cell antitumor activity by modulating mTOR pathway and APC function. , 2021, 9, e003339.		14
139	Beyond ABC: Another Mechanism of Drug Resistance in Melanoma Side Population. Journal of Investigative Dermatology, 2012, 132, 2317-2319.	0.3	13
140	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. Molecular Cancer Research, 2020, 18, 1560-1573.	1.5	13
141	Enhancing the evaluation of <scp>PI</scp>3K inhibitors through 3DÂmelanoma models. Pigment Cell and Melanoma Research, 2016, 29, 317-328.	1.5	12
142	Recent Advances in Melanoma and Melanocyte Biology. Journal of Investigative Dermatology, 2017, 137, 557-560.	0.3	12
143	A Melanoma Patient-Derived Xenograft Model. Journal of Visualized Experiments, 2019, , .	0.2	11
144	Frontiers in pigment cell and melanoma research. Pigment Cell and Melanoma Research, 2018, 31, 728-735.	1.5	10

#	Article	IF	Citations
145	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. Cell Death and Disease, 2020, 11, 882.	2.7	10
146	A Modified Nucleoside 6-Thio-2â€²-Deoxyguanosine Exhibits Antitumor Activity in Gliomas. Clinical Cancer Research, 2021, 27, 6800-6814.	3.2	10
147	Driving in the melanoma landscape. Experimental Dermatology, 2009, 18, 506-508.	1.4	9
148	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Research, 2021, 81, 5230-5241.	0.4	9
149	Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma. Oncogene, 2021, 40, 1659-1673.	2.6	8
150	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer, 2022, 4, zcac014.	1.6	7
151	Introduction. Cancer and Metastasis Reviews, 2005, 24, 193-194.	2.7	6
152	NUMB as a Therapeutic Target for Melanoma. Journal of Investigative Dermatology, 2022, 142, 1882-1892.e5.	0.3	5
153	Combination Therapy of Immunocytokines with Ipilimumab: A Cure for Melanoma?. Journal of Investigative Dermatology, 2013, 133, 595-596.	0.3	4
154	There is a world beyond protein mutations: the role of nonâ€coding <scp>RNA</scp>s in melanomagenesis. Experimental Dermatology, 2013, 22, 303-306.	1.4	4
155	Roadmap for New Opportunities in Melanoma Research. Seminars in Oncology, 2007, 34, 566-576.	0.8	3
156	Embryonic Stem Cells as a Model for Studying Melanocyte Development. Methods in Molecular Biology, 2009, 584, 301-316.	0.4	3
157	Relapse of melanoma after successful adoptive Tâ€cell therapy: escape through inflammationâ€induced phenotypic melanoma cell plasticity. Pigment Cell and Melanoma Research, 2013, 26, 2-3.	1.5	2
158	Farming cells to rebuild skin and melanoma. Cancer Biology and Therapy, 2007, 6, 467-471.	1.5	1
159	Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. Methods in Molecular Biology, 2015, , 1.	0.4	1
160	Role of stem cells in melanoma progression: hopes for a better treatment. Expert Review of Dermatology, 2007, 2, 191-201.	0.3	0
161	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. Expert Review of Dermatology, 2007, 2, 179-190.	0.3	0
162	Boris Bastian. Pigment Cell and Melanoma Research, 2010, 23, 834-834.	1.5	0

#	ARTICLE	IF	CITATIONS
163	Randy Lomax, 1947-2016. Pigment Cell and Melanoma Research, 2016, 29, 605-606.	1.5	0
164	Production of Humanized Mouse via Thymic Renal Capsule Grafting, CD34⁺ Cells Injection, and Cytokine Delivery. Journal of Visualized Experiments, 2021, , .	0.2	0